RenovoRx (NASDAQ:RNXT - Get Free Report) was upgraded by analysts at Wall Street Zen to a "sell" rating in a note issued to investors on Friday.
RNXT has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and issued a $3.00 price target on shares of RenovoRx in a research note on Monday, May 19th. Ascendiant Capital Markets raised their price objective on shares of RenovoRx from $11.00 to $11.50 and gave the stock a "buy" rating in a report on Thursday.
Read Our Latest Report on RenovoRx
RenovoRx Trading Down 0.7%
NASDAQ:RNXT traded down $0.01 during trading hours on Friday, hitting $1.39. The stock had a trading volume of 107,655 shares, compared to its average volume of 94,654. The company has a market cap of $50.84 million, a PE ratio of -2.44 and a beta of 1.32. The business has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $1.16. RenovoRx has a 1-year low of $0.75 and a 1-year high of $1.69.
RenovoRx (NASDAQ:RNXT - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.23 million. Research analysts expect that RenovoRx will post -0.4 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of RNXT. Citadel Advisors LLC acquired a new stake in shares of RenovoRx during the 4th quarter valued at approximately $49,000. HighTower Advisors LLC bought a new stake in RenovoRx during the first quarter valued at $40,000. Renaissance Technologies LLC acquired a new stake in shares of RenovoRx during the fourth quarter worth $84,000. Chicago Partners Investment Group LLC bought a new position in shares of RenovoRx in the 1st quarter worth about $97,000. Finally, Corsair Capital Management L.P. acquired a new position in shares of RenovoRx in the 1st quarter valued at about $186,000. Institutional investors own 3.10% of the company's stock.
RenovoRx Company Profile
(
Get Free Report)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider RenovoRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RenovoRx wasn't on the list.
While RenovoRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
